CytoDyn Inc (OTCMKTS:CYDY) is trading slightly lower after yesterday’s gain of 8%.
As of 10:47, CYDY stock fell by 3% at $1.99. The stock has traded 579K shares, compared to its average volume of 4.19 million shares. The stock opened at $1.89 and moved in a range of $1.8800 – 2.0400.
CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines
- announced that Chiral Pharma Corporation in the Philippines placed its first purchase order for leronlimab under a Compassionate Special Permit (“CSP”) to treat critically ill COVID-19 patients in the Philippines. The Company expects to recognize revenues related to this purchase order upon fulfillment of the purchase order and the terms of the agreement.
Chris Recknor, M.D., Chief Operating Officer and Head of Clinical Development of CytoDyn, said, “Current Philippine CSP data is significant for 21% mortality rate which is below that observed in CD12. One of the patient successes was recently reported last week on One News Philippines TV station. This patient had severe COVID-19 with deteriorating lung function despite treatment with antivirals and steroids. Testing was significant for high inflammation in the blood with Ferritin 17x elevated. Oxygen saturation on maximum oxygen flow was only 82% (normal >95%).
Twenty hours after receiving 700 mg of leronlimab subcutaneously at the patient’s home, the patient’s heart rate decreased from 120s to low 90s. Shortly thereafter the patient regained appetite, improved lung function, and had reduced inflammation with Ferritin down to 4x elevated. At week two, the patient successfully went off oxygen shortly after second dose also given at home. At week three, the patient continued to improve in stamina and returned to routine physical activities. Inflammation markers were still elevated with Ferritin still two times elevated, so a third dose was given. At week four, the patient is currently back to normal life activities.”